Edgar Filing: BIENAIME JEAN JACQUES - Form 4

BIENAIME Form 4 April 09, 20 FORN Check t if no lor subject Section Form 4 Form 5 obligati may con <i>See</i> Inst 1(b).	M 4 his box nger to 16. or ons ntinue. rruction STATEN STATEN STATEN Section 170	STATES S MENT OF C rsuant to Sec (a) of the Pul	CURITIES AND EXCHANGE Washington, D.C. 20549 HANGES IN BENEFICIAL OV SECURITIES ion 16(a) of the Securities Exchar lic Utility Holding Company Act he Investment Company Act of 19	WNERSHIP OF nge Act of 1934, of 1935 or Sectio	OMB Number Expires: Estimate burden respons	January 31, 2005 ed average hours per	
1. Name and Address of Reporting Person <u>*</u> BIENAIME JEAN JACQUES			Issuer Name and Ticker or Trading nbol OMARIN PHARMACEUTICAL C [BMRN]	 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 			
(Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.			Date of Earliest Transaction onth/Day/Year) /05/2018	_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer			
SAN RAF.	(Street) AEL, CA 94901		f Amendment, Date Original ed(Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities A	cquired, Disposed o	of, or Benefi	cially Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Da any (Month/Day/	Code (Instr. 3, 4 and 5)	SecuritiesCBeneficiallyFOwnedIFollowingCReported(5. Dwnership Form: Direct (D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	04/05/2018	04/05/2018	M 1,000 A ^{\$} 14.39	290,031 I	C		
Common Stock				182,201 I	[Shares held by Jean-Jacques Bienaime Family Trust	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy Common Stock)	\$ 14.39	04/05/2018	04/05/2018	М	1,000	11/12/2009	05/11/2019	Common Stock	1,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	Х		Chief Executive Officer			
Signatures						
/s/ Laura Randall Woodhead, Attorney-in-Fact	04/09	9/2018				
**Signature of Reporting Person	Da	ate				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects the number of options outstanding after the transactions from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.